PDFs by language
Our 24/7 cancer helpline provides support for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
At our National Cancer Information Center trained Cancer Information Specialists can answer questions 24 hours a day, every day of the year to empower you with accurate, up-to-date information to help you make educated health decisions. We connect patients, caregivers, and family members with valuable services and resources.
Or ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Abou-Alfa GK, Jarnagin W, Lowery M, D’Angelica M, Brown K, Ludwig E, Covey A, Kemeny N, Goodman KA, Shia J, O’Reilly EM. Liver and bile duct cancer. In: Neiderhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, PA. Elsevier; 2014:1373-1395.
Aherne EA, Pak LM, Goldman DA, Gonen M, Jarnagin WR, Simpson AL, Do RK. Intrahepatic cholangiocarcinoma: Can imaging phenotypes predict survival and tumor genetics? Abdom Radiol. 2018 Feb [Epub ahead of print].
Aloia TA. Precision Hilar cholangiocarcinoma surgery [Editorial]. Ann Surg Oncol. 2018 Mar; [Epub ahead of print].
American Cancer Society. Cancer Facts & Figures 2018. Atlanta, Ga: American Cancer Society; 2018.
American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010: 201-205; 295-325.
Antwi SO, Mousa OY, Patel T. Racial, ethnic, and age disparities in incidence and survival of intrahepatic cholangiocarcinoma in the United States: 1995-2014. Annals of Hepatology. 2018 Mar-Apr;17(2):274-285.
Blair AB, Murphy A. Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Curr Probl Cancer. 2017 Oct [Epub ahead of print].
DeLeon TT, Ahn DH, Bogenberger JM, Anastasiadis PZ, Arora M, Ramanathan RK, Aqel BA, Vasmatzis G, Truty MJ, Oklu R, Bekaii-Saab TS, Borad MJ. Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. Future Oncol. 2018; 14(6):553-566.
Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017.
Hoyos S, Navas M-C, Restrepo J-C, Botero RC. Current controversies in cholangiocarcinoma. Molecular Basis of Disease. 2017 July;1864:1461-1467.
Koca YS, Bulbul M, Barut I. The diagnostic roles of cytokines in hepatobiliary cancer. BioMed Res Inter. 2017; 2017(ID2979307):1-5.
Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, Gapstur S, Patel AV, Andrews K, Gansler T; American Cancer Society 2010 Nutrition and Physical Activity Guidelines Advisory Committee. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012 Jan-Feb;62(1):30-67.
Lee SJ, Kim JE, Kim ST, Lee J, Park SH, Park JO, Kang WK, Park YS, Lim HY. The correlation between serum chemokines and clinical outcome in patients with advanced biliary tract cancer. Translational Oncology. 2018; 11:353-357.
Lombardi P, Marino D, Fenocchio E, Chila, G, Aglietta M, Leone F. Emerging molecular target antagonists for the treatment of biliary tract cancer. Expert Opinion on Emerging Drugs. 2018 Feb;23(1):63-75.
Luvira V, Satitkarnmanee E, Pugkhem A, Kietpeerakool C, Lumbiganon P, Kamsa-ard S, Pattanittum P. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma. Cochrane Database of Systematic Reviews. 2017; 9(CD012814).
National Cancer Institute. Physician Data Query (PDQ). Bile Duct (Cholangiocarcinoma) Cancer Treatment. 03/14/2018. Accessed at https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq on March 29, 2018.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. v.1.2018. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf on March 29, 2018.
Patel T, Borad MJ. Carcinoma of the biliary tree. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins 2015:715-735.
Petrick JL, Campbell PT, Koshiol J, Thistle JE, Andreotti G, Beane-Freeman LE, Buring JE, Chan AT, Chong DQ, Doody MM, Gapstur SM….McGlynn KA. Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project. British J Cancer. 2018 Mar [Epub ahead of print].
Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma: Evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018 Mar;15(2):95-111.
Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya K S, Schwartz AL, Bandera E V, Hamilton KK, Grant B, McCullough M, Byers T, Gansler T. Nutrition and physical activity guidelines for cancer survivors. CA: A Cancer Journal for Clinicians. 2012 Jul-Aug;62(4):242–274.